0
0
The United States Food and Drug Administration (FDA) has expanded its approval of Sanofi’s quadrivalent meningococcal vaccine, MenQuadfi, to include infants as young as six weeks old. This landmark decision, announced on May 27, 2025, marks the first time a meningococcal vaccine is authorized for use in this age group in the United States.
MenQuadfi, which protects against invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W, and Y, was previously approved for individuals aged two years and older. With this new approval, healthcare providers can offer the vaccine to children aged 6 weeks to 23 months, addressing a population considered at particularly high risk for meningococcal infections.
“With this expanded indication, healthcare professionals can now offer MenQuadfi to infants as young as 6 weeks of age to help protect them against IMD caused by N. meningitidis serogroups A, C, W, and Y,” a Sanofi spokesperson stated.
Rising Cases and Clinical Evidence
The FDA’s decision comes amid a notable increase in meningococcal disease cases in the US, with preliminary CDC data showing 503 confirmed or probable cases last year—the highest since 2013. Infants under one year old are at the greatest risk of severe complications from meningococcal infections, which can lead to life-threatening bloodstream infections and inflammation of the brain and spinal cord.
Approval was based on results from three late-stage clinical trials involving over 6,000 infants and toddlers aged six weeks to 19 months. The studies demonstrated that MenQuadfi was as effective as existing vaccines, such as GSK’s Menveo, when administered alongside standard pediatric immunizations. No unexpected safety concerns were identified in these trials.
Next Steps and Recommendations
Currently, the US Centers for Disease Control and Prevention (CDC) recommends routine meningococcal vaccination for adolescents and for younger children at increased risk. The CDC’s Advisory Committee on Immunization Practices (ACIP) is expected to vote on formal recommendations for the use of MenQuadfi in infants and toddlers at its upcoming meeting in June 2025.
Dr. Tina Tan, President of the Infectious Diseases Society of America, emphasized the significance of the approval: “These younger individuals are at much higher risk of getting disease and having complications. This is not something that is new, because there are many countries that have recommendations to give a meningococcal vaccine to the younger pediatric population to protect them”.
MenQuadfi is now the only MenACWY vaccine available for individuals from six weeks of age with no upper age limit, supplied as a fully liquid solution in a single-dose vial for easier administration.
Disclaimer:
This article is based on publicly available information as of May 28, 2025, including statements from regulatory agencies, company press releases, and expert commentary. It is intended for informational purposes only and should not be considered medical advice. For decisions regarding vaccination, consult a qualified healthcare professional.
Citations:
